KRAS and familial pancreatic carcinoma: 37 A retrospective study revealed that for patients with advanced pancreatic cancer, tumour stage, chemotherapy, circulating regulatory T cells, CA19-9 levels, CA125 levels, and KRAS G12D and G12V mutations are significantly associated with OS.